PubMed Health⌕ Search

PubMed · 15260590

Cumulative isomerization probability studied by various transition state wave packet methods including the MCTDH algorithm. Benchmark: HCN-->CNH isomerization.

Abstract

The 3D cumulative isomerization probability N(E) for the transfer of a light particle between two atoms is computed by one time-independent and two time-dependent versions of the transition state wave packet (TSWP) method. The time-independent method is based on the direct expansion of the microcanonical projection operator on Chebyshev polynomials. In the time-dependent TSWP methods, the propagations are carried out by the split operator scheme and the multiconfiguration time-dependent Hartree (MCTDH) algorithm. This is the very first implementation of the TSWP method in the Heidelberg MCTDH package [G. W. Worth, M. H. Beck, A. Jackle, and H.-D. Meyer, The MCDTH package, Version 8.2 (2000); H.-D Meyer, Version 8.3 (2002). See http://www.pci.uni-heidelberg.de/tc/usr/mctdh/]. The benchmark is the HCN-->CNH isomerization for zero total angular momentum. Particular insights are given into the tunneling region. In larger systems, the time-dependent version of TSWP making use of the MCTDH algorithm will permit to treat more and more modes quantum mechanically, for very accurate results. Therefore, it was important to calibrate the implementation. Besides, we also assess the efficiency of a reduced dimensionality approach by comparing the new exact 3D calculations of N(E) for the HCN-->CNH isomerization with results obtained via 1D or 2D active subspaces. This suggests that, it should be possible to take directly benefit of the present 3D approaches, adapted for triatomic Jacobi coordinates to compute N(E) for H-transfer in larger systems, via three active coordinates. The prerequisite is then the simplification of the reduced 3D kinetic energy operator with rigid constraint to take the form corresponding to a pseudo triatomic system in Jacobi coordinates with effective masses. This last step is checked in the methoxy radical and malonaldehyde. Finally, different ways to obtain reliable eigenvectors of the flux operator associated with a dividing surface are revisited.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

B Lasorne, F Gatti, E Baloitcha, H-D Meyer, M Desouter-Lecomte. 2004-07-08. Cumulative isomerization probability studied by various transition state wave packet methods including the MCTDH algorithm. Benchmark: HCN-->CNH isomerization.. https://doi.org/10.1063/1.1760713

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗